Denali Therapeutics (DNLI) EPS (Weighted Average and Diluted) (2018 - 2026)
Denali Therapeutics (DNLI) reported EPS (Weighted Average and Diluted) of -$0.69 for Q1 2026, up 11.54% year-over-year from -$0.62 in Q1 2025, and up 5.48% on a QoQ basis from -$0.73 in Q4 2025.
Denali Therapeutics (DNLI) has 9 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.69 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 11.54% year-over-year to -$0.69 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.88 (down 7.46% YoY) and the FY2025 annual result came in at -$2.97, down 15.56% from the prior year.
- EPS (Weighted Average and Diluted) climbed to -$0.69 in Q1 2026 per DNLI's latest filing, from -$0.73 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $1.3 in Q2 2023 and bottomed at -$0.87 in Q4 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.72 (2023), against an average of -$0.58.
- The widest annual swing landed in 2023, when EPS (Weighted Average and Diluted) surged 370.83%; it then tumbled 145.38% in 2024.
- Tracing DNLI's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.75 in 2022, then slipped by 16.0% to -$0.87 in 2023, then climbed by 21.84% to -$0.68 in 2024, then slipped by 7.35% to -$0.73 in 2025, then gained by 5.48% to -$0.69 in 2026.
- Per Business Quant, the three latest DNLI EPS (Weighted Average and Diluted) figures stand at -$0.69 (Q1 2026), -$0.73 (Q4 2025), and -$0.74 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | -0.69 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.69 |
| Dec 31, 2025 | -0.73 |
| Sep 30, 2025 | -0.74 |
| Jun 30, 2025 | -0.72 |
| Mar 31, 2025 | -0.78 |
| Dec 31, 2024 | -0.68 |
| Sep 30, 2024 | -0.63 |
| Jun 30, 2024 | -0.59 |
| Mar 31, 2024 | -0.68 |
| Dec 31, 2023 | -0.87 |
| Sep 30, 2023 | -0.72 |
| Jun 30, 2023 | 1.30 |
| Mar 31, 2023 | -0.80 |
| Dec 31, 2022 | -0.75 |
| Sep 30, 2022 | -0.84 |
| Jun 30, 2022 | -0.48 |
| Mar 31, 2022 | -0.53 |
| Dec 31, 2021 | -0.62 |
| Sep 30, 2021 | -0.69 |
| Jun 30, 2021 | -0.50 |
| Mar 31, 2021 | -0.58 |
| Dec 31, 2020 | 2.28 |
| Sep 30, 2020 | -0.54 |
| Jun 30, 2020 | -0.56 |
| Mar 31, 2020 | -0.55 |
| Dec 31, 2019 | -0.60 |
| Dec 31, 2018 | 0.84 |